MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

Search

IQVIA Holdings Inc

Gesloten

SectorGezondheidszorg

227.05 0.16

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

223.6

Max

227.47

Belangrijke statistieken

By Trading Economics

Inkomsten

66M

332M

Verkoop

83M

4.1B

K/W

Sectorgemiddelde

30.402

78.892

Winstmarge

8.098

Werknemers

91,000

EBITDA

102M

883M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+7.9% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

722M

38B

Vorige openingsprijs

226.89

Vorige sluitingsprijs

227.05

Nieuwssentiment

By Acuity

50%

50%

149 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

IQVIA Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 dec 2025, 22:03 UTC

Belangrijke Marktbewegers

Mining Stocks Slip Near the End of Stellar Year

29 dec 2025, 15:57 UTC

Belangrijke Marktbewegers

Praxis Shares Rise on Ulixacaltamide Breakthrough Designation

29 dec 2025, 23:43 UTC

Marktinformatie

Nikkei May Decline; Yen in Focus -- Market Talk

29 dec 2025, 23:38 UTC

Acquisities, Fusies, Overnames

Manus: Will Continue to Operate From Singapore

29 dec 2025, 23:38 UTC

Acquisities, Fusies, Overnames

Manus: Will Continue to Sell, Operate Product Subscription Service Through App, Website

29 dec 2025, 23:37 UTC

Acquisities, Fusies, Overnames

Meta Platforms: Will Integrate Manus Service Into Products

29 dec 2025, 23:36 UTC

Acquisities, Fusies, Overnames

Meta Platforms: Will Continue to Operate, Sell Manus Service

29 dec 2025, 23:36 UTC

Acquisities, Fusies, Overnames

Meta Platforms: Manus's Talent to Join Team to Deliver General-Purpose Agents Across Consumer, Business Products

29 dec 2025, 23:35 UTC

Acquisities, Fusies, Overnames

Manus to Join Meta Platforms

29 dec 2025, 21:33 UTC

Acquisities, Fusies, Overnames

Origin: Raise Values Kraken at US$8.65 Billion

29 dec 2025, 21:33 UTC

Acquisities, Fusies, Overnames

Origin: Octopus Targeting Kraken Separation by Mid 2026

29 dec 2025, 21:31 UTC

Acquisities, Fusies, Overnames

BlueScope: Rezoning Will Allow for Range of Commercial, Industrial Development Uses

29 dec 2025, 21:31 UTC

Acquisities, Fusies, Overnames

BlueScope Also Says Land Adjacent to Port Kembla Steelworks Rezoned to Special Purpose

29 dec 2025, 21:30 UTC

Acquisities, Fusies, Overnames

Origin's Kraken Stake to Remain at 22.7%

29 dec 2025, 21:30 UTC

Acquisities, Fusies, Overnames

Origin Will Continue to Hold Its 22.7% Interest in Octopus

29 dec 2025, 21:30 UTC

Acquisities, Fusies, Overnames

BlueScope: Guidance Reflects Sustained Strength of Operating Performance in Recent Months

29 dec 2025, 21:30 UTC

Acquisities, Fusies, Overnames

Origin: Additional Interest Offsets Dilution From Raise

29 dec 2025, 21:30 UTC

Acquisities, Fusies, Overnames

BlueScope Doesn't Expect Material Impact on 1H Guidance Range

29 dec 2025, 21:29 UTC

Acquisities, Fusies, Overnames

Origin Waiving Australia Exclusivity to Kraken in Exchange for Additional 1.5% Equity Interest

29 dec 2025, 21:29 UTC

Acquisities, Fusies, Overnames

BlueScope Expects to Complete Property Sale for A$76 Million Consideration

29 dec 2025, 21:29 UTC

Acquisities, Fusies, Overnames

BlueScope Expects to Complete Property Sale in 2H of FY 2026

29 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

BlueScope: Selling Residentially Zoned Land in West Dapto to Large Homebuilder

29 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Origin: Kraken's Raise Paves Way for Separation From Octopus Energy

29 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Origin: Kraken to Raise Total US$1 Billion From New, Existing Investors

29 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

BlueScope Steel Exchanges Contracts for Sale of 33 Hectares of Land in West Dapto

29 dec 2025, 21:27 UTC

Acquisities, Fusies, Overnames

Origin Energy to Invest US$140M in Kraken's Standalone Equity Raise

29 dec 2025, 20:22 UTC

Marktinformatie

Oil Rebounds As Russia-Ukraine War Seen Continuing -- Market Talk

29 dec 2025, 20:14 UTC

Marktinformatie

U.S. Natural Gas Futures Rise As Front Month Expires -- Market Talk

29 dec 2025, 20:02 UTC

Acquisities, Fusies, Overnames

Union Pacific--Norfolk Southern Merger Targets Trucking Market Share -- Barrons.com

29 dec 2025, 17:36 UTC

Marktinformatie

U.S. Natural Gas Inventories Swing to Deficit Vs. 5-Year Average -- Market Talk

Peer Vergelijking

Prijswijziging

IQVIA Holdings Inc Prognose

Koersdoel

By TipRanks

7.9% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 244.85 USD  7.9%

Hoogste 273 USD

Laagste 200 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor IQVIA Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

12

Buy

3

Hold

0

Sell

Technische score

By Trading Central

150.68 / 153.45Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

149 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat